Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v1-EN
Language English English
Date Updated 2022-12-23 2022-11-08
Drug Identification Number 02241933 02241933
Brand name VIOKACE VIOKACE
Common or Proper name pancrelipase pancrelipase
Company Name NESTLE ENTERPRISES S.A. NESTLE ENTERPRISES S.A.
Ingredients AMYLASE PROTEASE LIPASE AMYLASE PROTEASE LIPASE
Strength(s) 113400UNIT 112500UNIT 20880UNIT 113400UNIT 112500UNIT 20880UNIT
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100 tablet bottles 100 tablet bottles
ATC code A09AA A09AA
ATC description DIGESTIVES, INCL ENZYMES DIGESTIVES, INCL ENZYMES
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2022-11-08 2022-11-08
Actual start date 2022-11-08 2022-11-08
Estimated end date Unknown Unknown
Actual end date 2022-12-22
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Drug product is being released today. A delay in finished product release testing has caused a shortage of product availability in the Canadian market. Nestle Health Science is actively working on resolving supply chain constraints and further updates will be provided as they become available.
Health Canada comments